Adjusted profit emerges. Legend Biotech Corporation (NASDAQ: LEGN) reported adjusted earnings per share of $0.01 for Q4 2025, marking a sharp turnaround from the $0.16 loss per share in the year-ago quarter. The biotech posted adjusted net income of $2.5 million, though GAAP results showed a net loss of $144.8 million, or $0.08 per diluted share. The quarter matched the prior quarter’s adjusted EPS of $0.01, signaling stabilization after a volatile 2025 that saw losses ranging from $0.22 to $0.68 per share in the first three quarters.
Revenue accelerates sharply. Revenue reached $306.3 million, up 64.2% from $186.5 million in Q4 2024. The top line held flat sequentially versus Q3’s $306.3 million, but the year-over-year comparison underscores the company’s commercial momentum. Gross profit of $182.8 million translated to a 59.7% gross margin, while cost of revenue totaled $32.5 million. Operating loss narrowed to $19.7 million, a substantial improvement from the deeper losses earlier in fiscal 2025.
Profitability trajectory matters most. The company’s ability to sustain adjusted profitability while scaling revenue will determine whether the stock—trading at $18.97 with a $3.5 billion market cap—can reclaim its 52-week high of $45.30. With an earnings call underway at 8:00 AM ET, investors should focus on management’s commentary around operating leverage and the path to consistent GAAP profitability as manufacturing scale improves.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.